Orthopediatrics Corp (KIDS) · Oct 27, 2026 · Earnings
Beat — Revenue $72.7M vs ~$68.5M consensus; FY revenue guide raised to $270M-$273M
OrthoPediatrics earnings beat Q3 revenue expectations and lifted 2026 guidance, while adjusted EPS remained slightly below consensus.
OrthoPediatrics is scaling a pediatric-only orthopedic platform: trauma and deformity and scoliosis are the core growth engines, while its OPSB bracing business and multi-year product launch cycle are intended to expand the addressable market and improve capital efficiency. After Q2, management had already raised 2026 revenue guidance to $265 million-$269 million and was targeting annual free-cash-flow breakeven, so this quarter was mainly a test of whether that improvement was continuing.
Revenue clearly cleared expectations. Q3 revenue reached $72.7 million, up 19% year over year, versus published consensus of roughly $68.5 million—about a 6% top-line beat. Trauma and deformity grew 19% and scoliosis 18%, showing that the acceleration was broad rather than dependent on one product line.
| Metric | Q3 2026 | Q3 2025 / expectation | Read |
|---|---|---|---|
| Revenue | $72.7M | $61.2M / ~$68.5M consensus | Beat |
| GAAP net loss | $(5.9)M | $(11.8)M | Narrower loss |
| GAAP diluted loss per share | $(0.25) | $(0.50) | Improved year over year |
| Non-GAAP diluted loss per share | $(0.23) | $(0.24) | Slightly worse than ~$0.21 consensus |
| Gross margin | 74% | 74% | Flat |
| Adjusted EBITDA | $6.9M | $6.2M | Improved |
| Free cash flow | $1.6M | $(3.4)M | Turned positive |
| FY2026 revenue guidance | $270M-$273M | Prior $265M-$269M | Raised |
The earnings quality is mixed, not a clean double beat. The adjusted diluted loss per share of $0.23 was modestly worse than the roughly $0.21 consensus loss, even as adjusted EBITDA rose to $6.9 million from $6.2 million. Operating leverage is improving because operating expenses grew only 6% against 19% revenue growth, but the company remains GAAP-loss making and interest expense increased to $2.6 million from $1.8 million. The unchanged 74% gross margin also says the improvement is coming from scale and expense discipline, not better product economics. 〔0〕
Cash-flow progress is the most important business change. OrthoPediatrics generated $1.6 million of quarterly free cash flow after using $3.4 million a year earlier, supporting management’s annual breakeven target. That is a meaningful step for a company still investing in inventory, clinics, acquisitions and product launches, though nine-month free cash flow remained negative at $6.6 million.
The raised outlook strengthens the growth story, but does not eliminate execution risk. Full-year revenue guidance moved to $270 million-$273 million from $265 million-$269 million, while adjusted EBITDA at approximately $25 million, annual set deployment near $10 million and 2026 free-cash-flow breakeven were reiterated. The raise is directionally better than the prior expectation, but the company still had only $44.9 million in cash, short-term investments and restricted cash at quarter-end versus $62.9 million at year-end, reflecting the funding burden of expansion.
Bottom line: This advances the business story: growth is running ahead of expectations, the full-year outlook moved higher, and cash flow has begun to turn. But the slight adjusted-EPS miss and still-negative year-to-date free cash flow make it a mixed earnings report rather than an unqualified beat.
Q4 report and full-year 2026 cash-flow outcome
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!